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A B S T R A C T
The V600 BRAF mutation has been described as a key mutation in the pathogenesis of classical hairy cell
leukemia (c-HCL) cases without expression of a mutant immunoglobulin heavy chain (IgHV). Here we present a
rare case of c-HCL with neither V600 BRAF mutation nor the aforementioned IgHV variant successfully treated
with cladribine and review the current literature on its use in women of childbearing age/pregnancy.
1. Introduction
Classical hairy cell leukemia is a rare, chronic mature B-cell
lymphoproliferative disorder that exhibits specific morphologic, im-
munohistochemical and immunophenotypic features – expressing
CD20, CD22, CD25, CD11c, CD103, CD123 and annexin A1. In
2011, Tiacci et al. proposed a genetic lesion that accounted for all
studied cases of classical hairy cell leukemia—the V600E BRAF
mutation, which serves in the RAS signaling cascade to propagate cell
survival and division [1]. This mutation has been heralded as a key
mutation in the pathogenesis of classical hairy cell leukemia, with
BRAF-inhibitors being investigated in clinical trials for relapsed c-HCL
[2]. Here we present a rare case of wild type BRAF c-HCL in a newly
diagnosed woman of childbearing age.
1.1. Case presentation
A 29-year old woman is referred to the hematologist for pancyto-
penia. She denied any symptoms with an unremarkable physical exam.
Her complete blood count was significant for leukopenia with severe-
moderate neutropenia (ANC of 540), mild macrocytic anemia and mild
thrombocytopenia. Initial rheumatologic and nutritional work up for
pancytopenia was negative. Bone marrow flow cytometry revealed
extensive involvement by monotypic B cells whose morphology and
immunophenotype was consistent with c-HCL, expressing most char-
acteristic markers (Fig. 1). Cytogenetics were unable to be performed
due to inadequate initial sample and CT scan of the chest, abdomen,
and pelvis showed mild splenomegaly. She was V600 BRAF mutation
negative with unmutated, wild-type IgHV on PCR. She was referred for
oocyte cryopreservation prior to completing one cycle of cladribine,
which resulted in myelosuppression requiring transfusion, G-CSF and
was complicated by neutropenic fever. No infectious source was found
and repeat labs with bone marrow biopsy demonstrated complete
remission (CR) with persistent minimal residual disease (MRD) of 5%.
Although flow cytometry on hemodiluted bone marrow biopsy post
cladribine induction revealed no B-cell clonality, morphologic evalua-
tion showed focal B-cell infiltrate with increased size co-expressing
CD25, consistent with c-HCL and estimated at ~5% MRD. PCR was not
used to assess disease response since the PCR for BRAF was negative
on diagnosis. After 6 rounds of weekly rituximab, the patient remained
in complete remission with no evidence of disease on bone marrow
biopsy to date.
2. Discussion
The differential diagnosis for pancytopenia and splenomegaly in the
context of a hypercellular bone marrow and marrow fibrosis, as
indicated by the moderate to marked diffuse increase in reticulin fibers
(grade 2–3 on a scale of 0–3) includes hairy cell leukemia, myeloid
disorders such as myelodysplastic syndromes, myeloproliferative neo-
plasms, primary myelofibrosis, acute myeloid leukemia and systemic
mast cell disease [3]. Based on the morphology of the cells, classical
hairy cell leukemia (c-HCL), hairy cell leukemia variant (vHCL) and
splenic marginal zone lymphoma (SMZL) should be the main diag-
nostic considerations. The morphology of the atypical lymphocyte in
the bone marrow touch imprint (Fig. 1, A), diffuse infiltrate of the
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CD20 positive atypical B-cells (Fig. 1, B & C) in the bone marrow and
Annexin-1 (Fig. 1, D) positivity of these atypical B-cells confirms the
diagnosis of classical hairy cell leukemia. The BRAF V600E mutation is
considered key to the pathophysiology and diagnosis of c-HCL. In an
attempt to confirm Tiacci, Xi et al. found that 11% of the tested
population with c-HCL, without IgHV4-34, expressed wild-type BRAF,
alluding to an alternate mechanism of action behind the pathophysiol-
ogy of c-HCL in these patients. However, patients in this study were
seeking treatment for relapsed HCL and had completed at least one
cycle of cladribine, unlike our patient. While related wild-type BRAF
processes like variant Hairy Cell Leukemia (vHCL) and IgHV4-34+
hairy cell leukemia confer poorer prognoses, the prognosis of wild-type
BRAF in c-HCL is unknown; nonetheless, with 85–90% rates of CR
after one cycle of cladribine, our patient has responded similarly [4,5].
While BRAF inhibitors, like vemurafenib, have exhibited 30–40% CR
and 60% partial response rate in refractory c-HCL, in BRAF wild-type
cells, vemurafenib paradoxically increases gene transcription by sti-
mulating the kinase activity of BRAF dimers [6]. Therefore, with case
reports documenting BRAF V600 negative c-HCL, we may recommend
BRAF screening in exon 15 (v600) and 11 [7]. In addition to this, this
case highlights the dilemma surrounding cladribine exposure in a
woman of childbearing age attempting to conceive, for which minimal
data exists. Cladribine is a purine analog that inhibits the enzyme
adenosine deaminase, interfering with the cell's ability to transcribe
DNA. It is characterized as a FDA pregnancy category D where safety
and efficacy in children has not been established. The median age of
onset at 52 years and c-HCL shares a 4.2 to 1 male to female
predilection, indicating the low prevalence of c-HCL in women of
childbearing age [6]. In a PubMed literature search for “cladribine,
pregnancy”, there is only one case report of successful pregnancy POST
cladribine exposure [8]. Further literature search has shown successful
splenectomy in a pregnant patient with c-HCL followed by one cycle of
cladribine post 6 months breastfeeding, resulting in CR [9].
3. Conclusion
This is a rare case of BRAF V600 mutation negative c-HCL with
wild-type IgHV that we know of documented in the literature. Though
the long- term prognosis is unknown, initial response to cladribine is
similar to V600 BRAF c-HCL.
Fig. 1. A. Touch imprint (romanowsky stain) of the bone marrow core shows a oval lymphocyte with slightly dispersed chromatin, and pale blue moderately abundant cytoplasm with a
ill-defined ruffled border. B. Bone Marrow core (hematoxylin & eosin stain) is hyper-cellular for age with diffuse sheets of hairy cell infiltrates. C. Immunohistochemical stain CD20 (B-
cell marker) highlights the increased diffuse infiltrate of B-cells in the Bone Marrow core. D. Immunohistochemical stain Annexin-1 (lipocortin 1) highlights the hairy cell infiltrate.
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